A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination RegimenPD
Sponsor: Celgene
Protocol Number: PO-CL-MM-PI-003854
Start Date: 8/14/2014
Active, estimate end date – end of November 2020